Roanna Ruiz, an analyst from Leerink Partners, maintained the Buy rating on United Therapeutics (UTHR – Research Report). The associated price target was lowered to $418.00.
Roanna Ruiz has given her Buy rating due to a combination of factors that highlight United Therapeutics’ strong financial performance and strategic advancements. The company has consistently achieved double-digit revenue growth for 11 consecutive quarters, demonstrating robust commercial momentum. A significant contributor to this growth is the Tyvaso franchise, which has shown exceptional performance with a 25% year-over-year increase in revenue, driven by strong prescription demand in PAH and PH-ILD indications.
Additionally, United Therapeutics is actively progressing its pipeline with several clinical and regulatory initiatives that are expected to drive long-term value. The management’s strategic deployment of capital across research and development, business development, and potential share buybacks further supports the company’s growth prospects. Looking ahead, 2025 is anticipated to be a pivotal year with key data readouts for Tyvaso in IPF and the potential for continued growth in the PH-ILD market, despite new competitor entrants. These factors collectively underpin Ruiz’s Buy rating for United Therapeutics.
In another report released on April 30, TD Cowen also maintained a Buy rating on the stock with a $400.00 price target.
UTHR’s price has also changed moderately for the past six months – from $361.400 to $303.090, which is a -16.13% drop .